In two weeks’ time, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) will meet to discuss Lykos Therapeutics’ MDMA-assisted therapy for PTSD New Drug Application (NDA). While PDAC’s determination on whether the therapy should be approved is non-binding, the meeting—which is scheduled to run between 8:30 AM and 4:30 PM EST on June 4th—provides an opportunity for a first look at how…
